Asianet Newsable on MSN
Why did RGNX shares plummet 19% after-hours today?
REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating ...
In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results